Last updated: 17 July 2019 at 9:43am EST

Ventures Vii, Llc Vivo Vent... Net Worth




The estimated Net Worth of Ventures Vii, Llc Vivo Vent... is at least 45.8 百万$ dollars as of 28 February 2017. Ventures Vent owns over 425,000 units of MEI Pharma Inc stock worth over 184,135$ and over the last 12 years Ventures sold MEIP stock worth over 45,612,907$.

Ventures Vent MEIP stock SEC Form 4 insiders trading

Ventures has made over 12 trades of the MEI Pharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Ventures sold 425,000 units of MEIP stock worth 13,098,500$ on 28 February 2017.

The largest trade Ventures's ever made was selling 907,828 units of MEI Pharma Inc stock on 16 November 2016 worth over 20,907,279$. On average, Ventures trades about 268,459 units every 115 days since 2013. As of 28 February 2017 Ventures still owns at least 60,972 units of MEI Pharma Inc stock.

You can see the complete history of Ventures Vent stock trades at the bottom of the page.



Insiders trading at MEI Pharma Inc

Over the last 12 years, insiders at MEI Pharma Inc have traded over 26,282,680$ worth of MEI Pharma Inc stock and bought 597,450 units worth 2,541,200$ . The most active insiders traders include Ventures Vii, Llc Vivo Vent...Leaf Ventures Ii, L.P.New L...Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of 360,383$. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth 329,211$.



What does MEI Pharma Inc do?

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.



Complete history of Ventures Vent stock trades at Aclaris Therapeutics Inc、Codexis、MEI Pharma Inc

インサイダー
取引
取引
合計金額
Ventures Vii, Llc Vivo Vent...
販売 13,098,500$
28 Feb 2017
Ventures Vii, Llc Vivo Vent...
販売 20,907,279$
16 Nov 2016
Ventures Vii, Llc Vivo Vent...
購入する 4,999,995$
13 Oct 2015
Ventures Vii, Llc Vivo Vent...
購入する 146,872$
7 Oct 2015
Ventures Vii, Llc Vivo Vent...
販売 474,300$
8 Sep 2016
Ventures Vii, Llc Vivo Vent...
販売 369,300$
15 Aug 2016
Ventures Vii, Llc Vivo Vent...
販売 337,600$
3 Aug 2016
Ventures Vii, Llc Vivo Vent...
販売 2,459,790$
25 Oct 2013
Ventures Vii, Llc Vivo Vent...
販売 5,909,523$
1 Oct 2013
Ventures Vii, Llc Vivo Vent...
販売 55,614$
28 Jun 2013
Ventures Vii, Llc Vivo Vent...
販売 1,842,929$
11 Jun 2013
Ventures Vii, Llc Vivo Vent...
販売 158,072$
16 May 2013


MEI Pharma Inc executives and stock owners

MEI Pharma Inc executives and other stock owners filed with the SEC include: